Special Issue

Optimizing Treatment of Parkinson's Disease

Message from the Guest Editors

Effective treatments for symptomatic control of Parkinson's disease (PD) have developed during the last two decades. These include combinations of oral drugs as well as transdermal delivery and devices for subcutaneous and intestinal infusions that have been developed in parallel with deep-brain stimulation (DBS) for PD and other movement disorders. The scope of this Special Issue "Optimizing Treatment of Parkinson's Disease" is the latest approaches for meeting the need of continuous individualization of the therapies. Current research is expanding on optimization of treatment outcome in terms of efficacy, safety, and quality of life, and the rapid development of wearables and homebased monitoring technologies is encouraging. We invite researchers in the field to submit original research and review articles including (but not limited to) studies on the fine-tuning of treatments in PD and other movement disorders using objective movement analysis, DBS, personalized and precision medicine, pharmacogenomics, bioinformatics, integrative computational approaches and clinical biomarker discovery.

Guest Editors

Dr. Dag Nyholm

Department of Neuroscience, Neurology at Uppsala University, 75124 Uppsala, Sweden

Dr. Filip Bergquist

Department of Pharmacology at Institute of Neuroscience and Physiology, University of Gothenburg, 41296 Gothenburg, Sweden

Deadline for manuscript submissions

closed (5 November 2021)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/58505

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

